Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study. [electronic resource]
Producer: 20181015Description: 457-464 p. digitalISSN:- 1365-2893
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Amides
- Antiviral Agents -- administration & dosage
- Benzofurans -- administration & dosage
- Carbamates
- Cyclopropanes
- Drug Therapy, Combination -- adverse effects
- Drug-Related Side Effects and Adverse Reactions -- epidemiology
- Female
- Genotype
- Hepacivirus -- classification
- Hepatitis C, Chronic -- drug therapy
- Humans
- Imidazoles -- administration & dosage
- Male
- Middle Aged
- Quinoxalines -- administration & dosage
- Ribavirin -- administration & dosage
- Sulfonamides
- Sustained Virologic Response
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.